Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG4010 in prostate cancer
NCT00040170Phase 2Terminated
- Sponsor
- Transgene SA
- Start
- May 2002
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of TG4010 in prostate adenocarcinoma, sponsored by Transgene SA. Started May 2002; status: terminated.
02
Drugs
TG4010
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT00040170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040170.